Cardiff Oncology (formerly Trovagene Inc.) Revenue and Competitors
Estimated Revenue & Valuation
- Cardiff Oncology (formerly Trovagene Inc.)'s estimated annual revenue is currently $15M per year.
- Cardiff Oncology (formerly Trovagene Inc.)'s estimated revenue per employee is $300,000
- Cardiff Oncology (formerly Trovagene Inc.)'s total funding is $80.5M.
- Cardiff Oncology (formerly Trovagene Inc.) has 50 Employees.
- Cardiff Oncology (formerly Trovagene Inc.) grew their employee count by 19% last year.
Cardiff Oncology (formerly Trovagene Inc.) Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Cardiff Oncology (formerly Trovagene Inc.)?
Trovagene is a clinical-stage, precision medicine oncology therapeutics company. Trovagene’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome resistance, extend duration of response and increase overall survival.keywords:N/A
Number of Employees
Employee Growth %
Cardiff Oncology (formerly Trovagene Inc.) News
SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need (including KRAS-mutated colorectal cancer, pancreatic canc ...
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative •Pfizer invests $15 million in Cardiff Oncology common shares •Adam Schayowitz, Ph.D., MBA, Vice President, Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and M ...
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival -8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose (RP2D) of onvansertib 15 mg/m2 who were evalua ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|